Comparisons of analysis methods for proof-of-concept trials

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 1, 2013, Pages

  Karlsson, K E ^a   Vong, C ^a   Bergstrand, M ^a   Jonsson, E N ^a,b   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Exprimo NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ANALYSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIET RESTRICTION; DRUG DEVELOPMENT; FOLLOW UP; GLUCOSE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOMETRIC MODEL; PRIORITY JOURNAL; PROOF OF CONCEPT TRIAL; SIMULATION; STUDY DESIGN;

EID: 84881147779     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2012.24     Document Type: Article

References (50)

1. FDA. Challenge and Opportunity on the Critical Path to New Medical Products. (2004). Accessed 28 July 2012.
2. Orloff, J. et al. The future of drug development: advancing clinical trial design. Nat. Rev. Drug Discov. 8, 949-957 (2009).
3. Price Waterhouse Coopers. Pharma 2020 Series. (2007-2011). Accessed 28 July 2012.
4. Goldberger, M.J. et al. ASCPT Task Force for advancing pharmacometrics and integration into drug development. Clin. Pharmacol. Ther. 88, 158-161 (2010).
5. Barrett, J.S., Fossler, M.J., Cadieu, K.D. & Gastonguay, M.R. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J. Clin. Pharmacol. 48, 632-649 (2008). (Pubitemid 351503519)
6. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007). (Pubitemid 46950619)
7. Wang, Y. et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: Impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol 48, 146-156 (2008).
8. Zhang, L. et al. Model-based drug development: the road to quantitative pharmacology. J. Pharmacokinet. Pharmacodyn. 33, 369-393 (2006). (Pubitemid 44020386)
9. Jonsson, E.N. & Sheiner, L.B. More efficient clinical trials through use of scientific modelbased statistical tests. Clin. Pharmacol. Ther. 72, 603-614 (2002). (Pubitemid 36021000)
10. Powell, J.R. & Gobburu, J.V. Pharmacometrics at FDA: evolution and impact on decisions. Clin. Pharmacol. Ther. 82, 97-102 (2007). (Pubitemid 46944204)
11. Lockwood, P., Ewy, W., Hermann, D. & Holford, N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm. Res. 23, 2050-2059 (2006).
12. Industry., F.a.D.A.C.a.C.G.f. E9 Statistical Principles for Clinical Trials. (1998).
13. Lees, K.R. et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588-600 (2006). (Pubitemid 43209106)
14. Krams, M., Lees, K.R., Hacke, W., Grieve, A.P., Orgogozo, J.M. & Ford, G.A. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 34, 2543-2548 (2003). (Pubitemid 37392736)
15. Hacke, W. et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 8, 141-150 (2009).
16. Optimising Analysis of Stroke Trials Collaboration. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches. Int J Stroke 3, 78-84 (2008).
17. Young, F.B., Lees, K.R. & Weir, C.J. Improving trial power through use of prognosisadjusted end points. Stroke. 36, 597-601 (2005). (Pubitemid 40344162)
18. Karlsson, K.E., Wilkins, J.J., Jonsson, F., Zingmark, P.H., Karlsson, M.O. & Jonsson, E.N. Modeling disease progression in acute stroke using clinical assessment scales. AAPS J. 12, 683-691 (2010).
19. Jonsson, F., Marshall, S., Krams, M. & Jonsson, E.N. A longitudinal model for non-monotonic clinical assessment scale data. J. Pharmacokinet. Pharmacodyn. 32, 795-815 (2005). (Pubitemid 41772358)
20. Skelly, A.H. Type 2 diabetes mellitus. Nurs. Clin. North Am. 41, 531-47, vi (2006). (Pubitemid 44584998)
21. Hamrén, B., Björk, E., Sunzel, M. & Karlsson, M. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin. Pharmacol. Ther. 84, 228-235 (2008).
22. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997). (Pubitemid 27145429)
23. Marie Davidian, D.M.G. Nonlinear Models for Repeated Measurement Data (Chapman and Hall/CRC, Boca Raton, FL, 1995).
24. Statistical guide for clinical pharmacology & therapeutics. Clin Pharmacol Ther 88, 150-152 (2010).
25. Mallinckrodt, C.H., Clark, S.W., Carroll, R.J. & Molenbergh, G. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J. Biopharm. Stat. 13, 179-190 (2003). (Pubitemid 36523156)
26. Mallinckrodt, C.H., Kaiser, C.J., Watkin, J.G., Molenberghs, G. & Carroll, R.J. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin. Trials 1, 477-489 (2004).
27. Siddiqui, O., Hung, H.M. & O'Neill, R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J. Biopharm. Stat. 19, 227-246 (2009).
28. Wang, X. & Ting, N. A proof-of-concept clinical trial design combined with dose-ranging exploration. Pharm. Stat. 11, 403-409 (2012).
29. Hooker, A.C., Ueckert, S., Andrew, M., Karlsson, M.O., Ito, K. & Corrigan, B. Model-based trial optimization for phase II and III designs in Alzheimer's disease. (2011).
30. Plan, E.L., Karlsson, K.E. & Karlsson, M.O. Approaches to simultaneous analysis of frequency and severity of symptoms. Clin. Pharmacol. Ther. 88, 255-259 (2010).
31. Vong, C., Bergstrand, M., Nyberg, J. & Karlsson, M.O. Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J. 14, 176-186 (2012).
32. Cartwright, M.E. et al. Proof of concept: a PhRMA position paper with recommendations for best practice. Clin. Pharmacol. Ther. 87, 278-285 (2010).
33. Lindbom, L., Ribbing, J. & Jonsson, E.N. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75, 85-94 (2004). (Pubitemid 38798039)
34. Beal, S.L., Sheiner, L.B., Boeckmann, A. & Bauer R.J. NONMEM User's Guide (1989-2009). (Icon Development Solutions, Ellicott City, MD, 2009).
35. Wählby, U., Bouw, M.R., Jonsson, E.N. & Karlsson, M.O. Assessment of type I error rates for the statistical sub-model in NONMEM. J. Pharmacokinet. Pharmacodyn. 29, 251-269 (2002). (Pubitemid 35333142)
36. Wählby, U., Jonsson, E.N. & Karlsson, M.O. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokinet. Pharmacodyn. 28, 231-252 (2001). (Pubitemid 32643366)
37. Wählby, U., Matolcsi, K., Karlsson, M.O. & Jonsson, E.N. Evaluation of type I error rates when modeling ordered categorical data in NONMEM. J. Pharmacokinet. Pharmacodyn. 31, 61-74 (2004). (Pubitemid 38870190)
38. Lee, P.I. Design and power of a population pharmacokinetic study. Pharm. Res. 18, 75-82 (2001). (Pubitemid 32299625)
39. Lyden, P. et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 25, 2220-2226 (1994). (Pubitemid 24338379)
40. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333, 1581-1587 (1995).
41. Kowalski, K.G., Olson, S., Remmers, A.E. & Hutmacher, M.M. Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. Clin. Pharmacol. Ther. 83, 857-866 (2008). (Pubitemid 351704916)
42. Holford, N.H. & Peace, K.E. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci. U.S.A. 89, 11466-11470 (1992).
43. Ito, K. et al. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement. 7, 151-160 (2011).
44. Ito, K., Ahadieh, S., Corrigan, B., French, J., Fullerton, T. & Tensfeldt, T. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers. Dement. 6, 39-53 (2010).
45. Snoeck, E. et al. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharmacol. Ther. 87, 706-713 (2010).
46. FDA. FDA Pharmacometrics. (2006).
47. Holford, N.H., Chan, P.L., Nutt, J.G., Kieburtz, K. & Shoulson, I. Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J. Pharmacokinet. Pharmacodyn. 33, 281-311 (2006). (Pubitemid 44020383)
48. Lacroix, B.D., Lovern, M.R., Stockis, A., Sargentini-Maier, M.L., Karlsson, M.O. & Friberg, L.E. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 86, 387-395 (2009).
49. Karlsson, M.O. et al. A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin. Pharmacol. Ther. 68, 175-188 (2000). (Pubitemid 30659173)
50. Bizzotto, R., Zamuner, S., De Nicolao, G., Karlsson, M.O. & Gomeni, R. Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J. Pharmacokinet. Pharmacodyn. 37, 137-155 (2010).